NIH Clinical Center Search the Studies: Study Number, Study Title

Protocol Details

Individualized Response Assessment to Heated Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Peritoneal Carcinomatosis from Ovarian, Colorectal, Appendiceal, or Peritoneal Mesothelioma Histologies

This study is currently recruiting participants.

Summary | Eligibility | Citations | Contacts




Sponsoring Institute

National Cancer Institute (NCI)

Recruitment Detail

Type: Participants currently recruited/enrolled
Gender: Male & Female
Min Age: 18 Years
Max Age: N/A

Referral Letter Required


Population Exclusion(s)

Pregnant Women;


cytoreductive surgery (CRS);
SMART System;
Peritoneal Metastasis

Recruitment Keyword(s)



Peritoneal Carcinomatosis;
Peritoneal Mesothelioma;
Ovarian Cancer;
Gastrointestinal Cancer;
appendiceal cancer

Investigational Drug(s)


Investigational Device(s)



Drug: Mitomycin C
Drug: Cisplatin
Procedure/Surgery: Heated Intraperitonial Chemotherapy
Drug: Doxorubicin
Drug: Oxaliplatin
Drug: 5-Fluorouracil
Drug: Sodium Thiosulfate

Supporting Site

National Cancer Institute


Cytoreductive surgery (CRS) removes tumors in the abdomen. HIPEC is heated chemotherapy that washes the abdomen. CRS and HIPEC may help people with peritoneal carcinomatosis. These are tumors that have spread to the lining of the abdomen from other cancers. Researchers think they can improve results of CRS and HIPEC by choosing the chemotherapy drugs used in HIPEC.


To see if HIPEC after CRS can be improved, by testing different chemotherapy drugs, using a model called the SMART (Sample Microenvironment of Resected Metastatic Tumor) System.


Adults ages 18 and older who have peritoneal carcinomatosis that cannot be fully removed safely with surgery.


Participants will be screened with:

Medical history

Physical exam

Blood and urine tests

Computed tomography (CAT) scan

Other imaging scans, as needed

Electrocardiogram (EKG)

Tumor biopsy, if needed

Laparoscopy. Small cuts will be made in the abdomen. A tube with a light and a camera will be used to see their organs.

Some screening tests will be repeated in the study.

Participants will enroll in NIH protocol #13C0176. This allows their tumor samples to be used in future research.

Participants will have CRS. As many of their visible tumors will be removed as possible. They will also have HIPEC. Two thin tubes will be put in their abdomen. They will get chemotherapy through one tube. It will be drained out through the other tube. They will be in the hospital for 7-21 days after surgery.

Participants will give tumor, blood, and fluid samples for research. They will complete surveys about their health and quality of life.

Participants will have follow-up visits over 5 years.

--Back to Top--



-Confirmation of peritoneal carcinomatosis from appendiceal, colorectal, ovarian, or peritoneal mesothelioma histologies by the Laboratory of Pathology, NCI.

-Measurable or evaluable disease as defined by RECIST v1.1. criteria and/or by peritoneal carcinomatosis index (PCI) score.

-Participants must be assessed to be able to undergo complete cytoreduction, with laparoscopically assessed PCI score thresholds as indicated below:

Primary Histology:



PCI Cutoff for Eligibility:

Total Score < 20 (out of 39 possible points)

Total Score <= 30 (out of 39 possible points)

-Age >= 18 years.

-ECOG performance status <= 1 (Karnofsky >= 80%).

-Participants must have adequate organ and marrow function as defined below:

--Absolute neutrophil count >= 1,000/mcL

--Platelets >= 75,000/mcL

--Total bilirubin within normal institutional limits

--AST (SGOT)/ ALT (SGPT) <= 3x institutional upper limit of normal (ULN), or <= 5.0x ULN in participants with liver metastases (only)

--Creatinine within normal institutional limits


--Creatinine clearance >= 60 mL/min/1.73 M^2 for participants with creatinine levels above institutional normal calculated using eGFR.

-Because therapeutic agents used in this trial are known to be teratogenic, women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for 180 days after last study treatment; should a woman suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.

-Ability of participant to understand and the willingness to sign a written informed consent document.

-Ability and willingness to co-enroll on the tissue collection protocol 13C0176, Tumor, Normal Tissue and Specimens from Patients Undergoing Evaluation or Surgical Resection of Solid Tumors .


-Participants with known extra-abdominal metastatic disease from the participant s appendiceal, colorectal, ovarian, or peritoneal mesothelioma primary.

-Participants who have received intraperitoneal chemotherapy or other anti-cancer therapy within the last 4 weeks prior to the start of study treatment.

-Participants who have undergone major surgery within the last 12 weeks prior to the start of study treatment.

-History of allergic reactions attributed to platinum-containing compounds.

-History of dihydropyrimidine dehydrogenase deficiency (only participants with appendiceal or colorectal cancer).

-Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.

-Pregnant women are excluded from this study because the protocol involves major abdominal surgery and chemotherapeutic agents with the potential for teratogenic or abortifacient effects; because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother, breastfeeding should be discontinued if the mother is undergoing treatment.

-HIV-positive participants with detectable viral load despite antiretroviral therapy are ineligible because of participants increased risk of lethal infections when treated with marrow-suppressive therapy. HIV-positive participants who have undetectable viral load on antiretroviral therapy may be considered for this study only after consultation with a NIAID physician.

--Back to Top--


Not Provided

--Back to Top--


Principal Investigator

Referral Contact

For more information:

Andrew M. Blakely, M.D.
National Cancer Institute (NCI)
NIHBC 10 - CRC BG RM 4-3760B
(240) 760-7647

Audra A. Satterwhite, R.N.
National Cancer Institute (NCI)
National Institutes of Health
Building 10
Room 4W5920
10 Center Drive
Bethesda, Maryland 20892
(240) 858-3552

NCI Referral Office
National Institute of Health Clinical Center (CC), 9000 Rockville Pike, Bethesda, Maryland 20892, United States: NCI Clinical Trials Referral Office

Clinical Trials Number:


--Back to Top--